AI Index / Tempus
Tempus (TEM)
Tempus' main sources of revenue are Genomics (clinical oncology and hereditary/genetic testing) and Data & Services (including data licensing and insights for pharma/biotech clients). AI directly contributes to the Data & Services segment, particularly through large-scale foundational model deals like the $200M AstraZeneca-Pathos partnership. AI also underpins Tempus' diagnostic advancements, leveraging multimodal datasets for precision medicine. The company positions AI as core to its differentiation in diagnostics, making it a primary direct driver of growth and new revenue streams.
Loading...
In addition, I’ll highlight just one other big piece of news which we put out about a week ago, which is we announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos in April to build the world’s largest foundation model in oncology.
- Eric Lefkofsky
Similar Companies in the Swift AI Index
Quotes from tempus Executives About Artificial Intelligence and Generative AI
When the model is complete, which we expect, the first version of the model will be complete in about nine to twelve months, each party will get a copy. AZ and Pathos to advance their drug discovery efforts, and Tempus to advance its diagnostic and data products.
- Eric Lefkofsky
It’s also important in that it’s a giant step in making precision medicine a reality. We’re closer than ever to understanding at a molecular level why patients do and don’t respond to cancer treatments.
- Eric Lefkofsky
...there’s lots of places to invest in both of our main businesses...building out our core AI applications and product set, including the foundation model that power a lot of this.
- Eric Lefkofsky
...the opportunity set to bring AI to health care at scale...you don’t want to under-invest...miss out on what could be one of the biggest technology opportunities of all time.
- Eric Lefkofsky
...if you look at the foundation model we're building, what it's essentially doing is pouring in an enormous amount of data...looking for associations between vast amounts of molecular data that we have been unable to ever interrogate connected to vast amounts of outcomes.
- Eric Lefkofsky